TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [14]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“TREM2 was recently demonstrated to be essential for promoting microglial cell association with plaques44–49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Although numerous studies have reported that TREM2 expression is upregulated in amyloid plaque-associated microglia in vivo (Frank et al., 2008; Jay et al., 2015), our research is the first to show that PU.1 knockdown abrogates this phenomenon in vitro.”
From PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease (2025) · cites this paper as Jay et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [59]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [16]
Experimental — accuracy not yet measured
34 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“5XFAD mice (The Jackson Laboratory B6SJL-Tg(APPSwFlLon,PSEN1*M146*l286V)) express mutant human APP(695) with Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations and human PSEN1 with M146L and L286V mutations under control of the Thy1 promoter (Oakley et al., 2006).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Notably, variants of the immune cell– specific triggering receptor expressed on myeloid cells 2 (TREM2) confer dramatically elevated risk for developing AD (R. Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 3×
“First, we found that TREM2+ cells in AD mouse models 2013; Butovsky et al., 2014), was expressed by parenchymal, nonplaque-associated cells in APPPS1;Trem2+/+ mice (Fig.”
BackgroundSelf-citationIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“TREM2, along with its obligate intracellular adaptor DAP12, was identified as a hub gene in systems biology analyses in AD (Forabosco et al., 2013; Zhang et al., 2013), highlighting the central importance of these myeloid cell signaling elements CORRESPONDENCE Bruce T.”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“However, recent genome-wide association studies linked polymorphisms in inflammation-related genes to increased AD risk, supporting the conclusion that inflammation can be a causative factor in disease pathology (Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“The potential role of peripherally derived macrophages in AD has been controversial (Prinz and Priller, 2014), but it is well accepted that CD45hiLy6C+CCR2+ monocytes enter the central nervous system (CNS) and modulate pathology in other disease contexts (Mildner et al.”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Cited by
Items 301–400 of 683
Pocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51
Self-citationNAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
“TREM2 KO/APPPS1 mice exhibit a reduction in inflammation and the accumulation of amyloid and tau [146], suggesting that TREM2 is involved in AD pathology.”
BackgroundDisease-associated microglia in neurodegenerative diseases: Friend or foe?
Cheng, Y.-H., & Ho, M. S.-C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003426 · Cited by 64
“In addition, the majority of loss-of-function studies indicate that Trem2 deletion exacerbates disease progression by suppressing DAM-associated gene expression [19,20,58] and promoting a shift toward a pro-inflammatory “M1” microglial state [59].”
Coşacak, M. İ., Bhattarai, P., Bocova, L., Dzewas, T., Mashkaryan, V., Papadimitriou, C., Brandt, K., Hollak, H., Antos, C. L., & Kızıl, Ç. (2017) · Scientific Reports · doi:10.1038/s41598-017-13311-5 · Cited by 57
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Selles, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179925 · Cited by 50
The role of TREM2 in Alzheimer’s disease: from the perspective of Tau
Huang, W., Huang, J., Huang, N., & Luo, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1280257 · Cited by 49
Carbajosa, G., Malki, K., Lawless, N., Wang, H., Ryder, J. W., Wozniak, E., Wood, K., Mein, C. A., Dobson, R. J. B., Collier, D. A., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.019 · Cited by 49
Wilkins, H. M., Koppel, S. J., Weidling, I. W., Roy, N., Ryan, L. N., Stanford, J. A., & Swerdlow, R. H. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9704-7 · Cited by 49
“…Signaling, 1:1000), CSF1R (Cell Signaling, 1:500), glial fibrillary acidic protein (GFAP) (Abcam, 1:1000), histone deacetylase 1 (HDAC1, Cell Signaling 1:2000), nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) p65 (Cell Signaling, 1:1000), and pNFĸB p65-Ser 536 (Abcam, 1:500).”
BackgroundSelective loss of 5hmC promotes neurodegeneration in the mouse model of Alzheimer's disease
Zhang, Y., Zhang, Z., Li, L., Xu, K., Ma, Z. S., Chow, H., Herrup, K., & Li, J. (2020) · The FASEB Journal · doi:10.1096/fj.202001271r · Cited by 54
Deming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
“…deficits and amyloid accumulation by 6 months (Wang et al, 2015), the APP/PS1 mouse model which develops amyloid accumulation 6–9 months and cognitive decline by 12 months (Jay et al, 2015), and the PS19 mouse model which is a model for tauopathy and has no amyloid pathology (Leyns et al, 2017).”
BackgroundInfluentialMa, Q.-L., Zhu, C., Morselli, M., Su, T., Pelligrini, M., Lu, Z., Jones, M., Denver, P., Castro, D., Gu, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558036 · Cited by 48
“In support of this concept, TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology at later stages in ADmousemodels (73).”
BackgroundCentral Nervous System Macrophages in Health and Disease
Hove, H. V., Feo, D. D., Greter, M., & Becher, B. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041334 · Cited by 53
Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases
Bossù, P., Spalletta, G., Caltagirone, C., & Ciaramella, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00632 · Cited by 54
“At variance, peripherally derived macrophages have a detrimental role in TREM2-deficient AD mice (40), suggesting that the function of infiltrating myeloid cells may be complex and dependent on cell subset and inflammatory context considered.”
BackgroundSleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway
Pak, V. M., Onen, S. ‐., Bliwise, D. L., Kutner, N. G., Russell, K. L., & Onen, F. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00069 · Cited by 56
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
“Another study reported that deficiency of TREM2, a microglial receptor, reduces immune activation and lowered Aβ burden in mice [55].”
BackgroundMa, Y., Hu, X., Karako, K., Song, P., Tang, W., & Xia, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1576020 · Cited by 54
Deficiency of a sulfotransferase for sialic acid-modified glycans mitigates Alzheimer’s pathology
Zhang, Z., Takeda‐Uchimura, Y., Foyez, T., Ohtake‐Niimi, S., Narentuya, Akatsu, H., Nishitsuji, K., Michikawa, M., Wyss‐Coray, T., Kadomatsu, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615036114 · Cited by 53
“AD model mice deficient in TREM2 have shown a reduction in Aβ-plaque–associating microglial/myeloid cells (27, 28) and age-dependent amelioration of amyloid pathology (28, 44).”
BackgroundCaspase-8, association with Alzheimer’s Disease and functional analysis of rare variants
Rehker, J., Rodhe, J., Nesbitt, R. R., Boyle, E. A., Martin, B. K., Lord, J., Karaca, I., Naj, A., Jessen, F., Helisalmi, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0185777 · Cited by 47
TREM2 expression and amyloid‐beta phagocytosis in Alzheimer's disease
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108626 · Cited by 50
“SNPs in the TREM2 gene modulate protein expression [17,18] and function, possibly resulting in an inactive receptor [17].”
BackgroundRong, Z., Cheng, B., Zhong, L., Ye, X., Li, X., Jia, L., Li, Y., Shue, F., Wang, N., Cheng, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000550rr · Cited by 46
Singh, A. K., Mishra, G., Maurya, A., Awasthi, R., Kumari, K., Thakur, A., Rai, A., Rai, G. K., Sharma, B., Kulkarni, G. T., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190903102822 · Cited by 48
Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
Chen, C., Li, X., Ge, G., Liu, J., Biju, K. C., Laing, S. D., Qian, Y., Ballard, C., He, Z., Masliah, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23795-4 · Cited by 44
Ali, F., Baringer, S. L., Neal, A., Choi, E. Y., & Kwan, A. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181190 · Cited by 43
“Previous studies have been either qualitative examinations of images [23, 49] or quantitative assessments of large undifferentiated regions (e.”
BackgroundZhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 51
“Our results demonstrated the feasibility of engineering highly effective TREM2 targeting antibody therapies for the treatment of early-onset AD.”
BackgroundInfluentialGlebov, K., Wunderlich, P., Karaca, I., & Walter, J. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0479-9 · Cited by 43
“However, cells associated with plaques in this model revealed characteristics of peripheral macrophages that might invade the brain [15].”
InfluentialLiu, P., Reichl, J. H., Rao, E. R., McNellis, B. M., Huang, E. S., Hemmy, L. S., Forster, C. L., Kuskowski, M. A., Borchelt, D., Vassar, R. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-161027 · Cited by 45
State of Play in Alzheimer’s Disease Genetics
Zhu, J.-B., Tan, C.-C., Tan, L., & Yu, J.-T. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170062 · Cited by 43
Monaghan, K. L., Zheng, W., Hu, G., & Wan, E. C. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02779 · Cited by 50
“Trem2 was shown to be expressed in the inflammatory macrophages and has a detrimental role in Alzheimer’s disease pathology (34).”
BackgroundDa Mesquita, S., & Rua, R. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.03.007 · Cited by 41
Neuroinflammation — using big data to inform clinical practice
Dendrou, C. A., McVean, G., & Fugger, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.171 · Cited by 48
“…our understanding of cellular heterogeneity is the ability to perform highly parallel, single-cell transcriptomics 73,74 ; for instance, application of this technology to mouse retinal tissue has defined 39 transcriptionally distinct cell populations, including potentially novel cell subsets 74 .”
BackgroundThe role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models
Karanfilian, L., Tosto, M. G., & Malki, K. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.004 · Cited by 41
Madadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
Cisternas, P., Taylor, X., & Lasagna‐Reeves, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246319 · Cited by 44
Tajbakhsh, A., Read, M., Barreto, G. E., Ávila-Rodriguez, M., Gheibi-Hayat, S. M., & Sahebkar, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173873 · Cited by 41
Maguire, E., Menzies, G. E., Phillips, T., Sasner, M., Williams, H. M., Czubala, M. A., Evans, N., Cope, E. L., Sims, R., Howell, G. R., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105603 · Cited by 41
“In microglia, PLC c 2 regulates multiple signalling pathways leading to functions such as phagocytosis, secretion of cytokines and chemokines, cell survival and proliferation (Ulrich et al , 2014; Jay et al , 2015; Wang et al , 2015).”
Self-citationCD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1
Lago, N., Pannunzio, B., Amo‐Aparicio, J., López‐Vales, R., & Peluffo, H. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.06.002 · Cited by 43
Xu, M., Zhang, L., Liu, G., Jiang, N., Zhou, W., & Zhang, Y. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180722 · Cited by 39
Ma, G., Liu, M., Du, K., Zhong, X., Gong, S., Jiao, L., & Wei, M. (2019) · BioMed Research International · doi:10.1155/2019/8179145 · Cited by 46
The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease
Zhong, L., & Chen, X.-F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00328 · Cited by 40
Furosemide as a Probe Molecule for the Treatment of Neuroinflammation in Alzheimer’s Disease
Wang, Z., Vilekar, P., Huang, J., & Weaver, D. F. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00445 · Cited by 42
Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?
Ouyang, F., Jiang, Z., Chen, X., Chen, Y., Wei, J., Xing, S., Zhang, J., Fan, Y., & Zeng, J. (2021) · Translational Stroke Research · doi:10.1007/s12975-021-00921-5 · Cited by 43
Gao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 51
“TREM2 is a key protein involved in the activation of microglia and AD mouse models have consistently found increased TREM2 expression during aging and disease progression [6, 144]; therefore, the question arises as to whether CSF sTREM2 would be an attractive candidate biomarker to track the disease.”
BackgroundImmunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
St-Amour, I., Cicchetti, F., & Calon, F. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1518-9 · Cited by 34
“Surprisingly, TREM2-deficient mice led to contrasting findings, either exacerbating or reducing amyloid pathologies [62, 163].”
BackgroundGoyal, K., Konar, A., Kumar, B. S. H., & Koul, V. (2018) · Nanoscale · doi:10.1039/c8nr03828g · Cited by 38
Current Therapeutic Targets for Alzheimer's Disease
Chaudhary, A., Maurya, P. K., Yadav, B. S., Singh, S., & Mani, A. (2018) · Journal of Biomedicine · doi:10.7150/jbm.26783 · Cited by 37
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0530-9 · Cited by 38
INPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model
Iguchi, A., Takatori, S., Kimura, S., Muneto, H., Wang, K., Etani, H., Ito, G., Sato, H., Hori, Y., Sasaki, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106375 · Cited by 42
Qiu, M., Zong, J., He, Q., Liu, Y., Wan, Y., Li, M., Zhou, Y., Wu, J., & Hu, B. (2022) · Aging and Disease · doi:10.14336/ad.2022.0212 · Cited by 41
Microglia in Alzheimer's Disease: A Role for Ion Channels
Thei, L., Imm, J., Kaisis, E., Dallas, M. L., & Kerrigan, T. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00676 · Cited by 36
“On the other hand, most studies in TREM2- deficient ADlike mice have shown reduced number of microglia around Aβ plaques (Jay et al., 2015; Wang et al., 2015).”
BackgroundMeprin β cleaves TREM2 and controls its phagocytic activity on macrophages
Berner, D. K., Wessolowski, L., Armbrust, F., Schneppenheim, J., Schlepckow, K., Koudelka, T., Scharfenberg, F., Lucius, R., Tholey, A., Kleinberger, G., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902183r · Cited by 36
Sokolova, D., Childs, T., & Hong, S. Y. (2021) · Faculty Reviews · doi:10.12703/r/10-19 · Cited by 39
Microglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease
Qu, W., & Li, L. (2021) · The Neuroscientist · doi:10.1177/10738584211040786 · Cited by 40
RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment
Lefterov, I., Schug, J., Mounier, A., Nam, K. N., Fitz, N. F., & Koldamova, R. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.019 · Cited by 36
Hwang, M., Savarin, C., Kim, J., Powers, J., Towne, N., Oh, H., & Bergmann, C. C. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02629-1 · Cited by 44
“Trem2−/− mice (Trem2tm1(KOMP)Vlcg) in which exons 2–4 of the Trem2 gene were replaced with LacZ resulting in loss of Trem2 function, were generated by the transNIH Knock-Out Mouse Project (KOMP) and kindly Keywords: TREM2, CNS, Virus, Demyelination, Microglia, BMDM, Phagocytosis, Coronavirus provided by Dr. Bruce T La…”
BackgroundThe Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention
Merlo, S., Spampinato, S. F., Caruso, G. I., & Sortino, M. A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200131105418 · Cited by 37
An overview of microglia ontogeny and maturation in the homeostatic and pathological brain
Mendes, M. S., & Majewska, A. K. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15225 · Cited by 39
Yu, F., Yu, N., Peng, J., Zhao, Y., Zhang, L., Wang, X., Xu, X., Zhou, J., & Wang, F. (2021) · The FASEB Journal · doi:10.1096/fj.202100157rr · Cited by 39
Luo, Q., Schnöder, L., Hao, W., Litzenburger, K., Decker, Y., Tomic, I., Menger, M. D., Fassbender, K. C., & Liu, Y. (2022) · Aging Cell · doi:10.1111/acel.13679 · Cited by 36
“One group reported that TREM2 deficiency in APPtransgenic mice increases hippocampal Aβ burden and accelerates neuron loss (Wang et al., 2015); however, another group showed that TREM2 deletion reduces cerebral Aβ accumulation (Jay et al., 2015).”
BackgroundHe, S., Li, X., Mittra, N., Bhattacharjee, A., Wang, H., Song, S., Zhao, S., Liu, F., & Han, X. (2025) · Advanced Science · doi:10.1002/advs.202410910 · Cited by 34
TREM2 enables amyloid β clearance by microglia.
Rivest, S. (2015) · Cell Research · doi:10.1038/cr.2015.37 · Cited by 34
Belloli, S., Pannese, M., Buonsanti, C., Maiorino, C., Di Grigoli, G., Carpinelli, A., Monterisi, C., Moresco, R. M., & Panina-Bordignon, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.010 · Cited by 34
Schwartz, M., Ramos, J. M. P., & Ben-Yehuda, H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900844 · Cited by 34
TMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities
Liu, Z., Ning, J., Zheng, X., Meng, J., Han, L., Zheng, H., Zhong, L., Chen, X., Zhang, X., Luo, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02874-3 · Cited by 37
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 34
Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 42
Scott‐Hewitt, N., Folts, C. J., Hogestyn, J. M., Piester, G., Mayer-Pröschel, M., & Noble, M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx153 · Cited by 33
Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Александровна, П. Е., Chernyuk, D., & Борисович, Б. И. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200528162046 · Cited by 34
Severini, C., Barbato, C., Certo, M. G. D., Gabanella, F., Petrella, C., Stadio, A. D., VINCENTIIS, M. D., Polimeni, A., Ralli, M., & Greco, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200621204546 · Cited by 35
“Indeed, protracted activation of the immune response induces a reactive microgliosis with a persistent secretion of pro-inflammatory molecules and the recruitment of peripheral macrophages into the brain, which in turn aggravate AD pathology [43, 47-49].”
BackgroundVariant TREM2 Signaling in Alzheimer's Disease
Olufunmilayo, E. O., & Holsinger, R. M. D. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167470 · Cited by 34
The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2
Shirotani, K., Hatta, D., Wakita, N., Watanabe, K., & Iwata, N. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac073 · Cited by 33
Subramanian, S., Pallati, P. K., Sharma, P., Agrawal, D. K., & Nandipati, K. C. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1187-7 · Cited by 33
“However, TREM-2 acts as an anti-inflammatory agent via enhanced anti-inflammatory cytokine transcription and production and regulates the excessive inflammation [22].”
BackgroundRetractedUnravelling the glial response in the pathogenesis of Alzheimer's disease
Alibhai, J. D., Diack, A. B., & Manson, J. C. (2018) · The FASEB Journal · doi:10.1096/fj.201801360r · Cited by 31
“It has been hypothesized that TREM2 mutations contribute to AD pathogenesis and thus could be a therapeutic target.”
ResultInfluentialCheng, B., Li, X., Dai, K., Duan, S., Rong, Z., Chen, Y., Lü, L., Liu, Z., Huang, X., Xu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633796 · Cited by 40
“Animals and Brain Stereotaxic Injection Short-Term Injection of CSF1 in Trem2 Mouse Brain TREM2 knockout (KO) mice (Trem2; C57BL/6) and wild type (WT) C57BL/6 littermates were obtained from the UC Davis Knockout Mouse Project (KOMP) repository as described previously (18) and were group housed (12 hr/12 hr light/dark)…”
MethodThe Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer’s Disease
Qin, Q., Wang, M., Yin, Y., & Tang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845897 · Cited by 40
“Other studies also point out TREM2 may affect the inflammatory response and energy metabolism, regulating microglial phagocytosis of abnormal proteins and damaged neurons (50, 52).”
BackgroundErythromyeloid-Derived TREM2: A Major Determinant of Alzheimer’s Disease Pathology in Down Syndrome
Raha-Chowdhury, R., Henderson, J. W., Raha, A. A., Stott, S. R. W., Vuono, R., Foscarin, S., Wilson, L., Annus, T., Fincham, R., Allinson, K., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170814 · Cited by 31
Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases
Han, J., Wang, M., Ren, M., & Lou, H. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1264072 · Cited by 30
“receptors, co-stimulatory molecules, inflammatory cytokines and trophic factors that are involve in microglial function in AD mice [31,32].”
BackgroundMilitary‐related risk factors for dementia
Snyder, H. M., Carare, R. O., DeKosky, S. T., de Leon, M. J., Dykxhoorn, D. M., Gan, L., Gardner, R. C., Hinds, S. R., Jaffee, M. S., Lamb, B. T., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.08.011 · Cited by 33
“[96] Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al.”
BackgroundSelf-citationMicroglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 36
Jain, S., Singh, R., Paliwal, S., & Sharma, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230511122435 · Cited by 37
TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 30
Hohsfield, L. A., Tsourmas, K. I., Ghorbanian, Y., Syage, A. R., Kim, S. J., Cheng, Y., Furman, S., Inlay, M. A., Lane, T. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24144 · Cited by 26
New Insights into Microglial Mechanisms of Memory Impairment in Alzheimer’s Disease
Li, N., Deng, M., Hu, G., Li, N., Yuan, H., & Zhou, Y. (2022) · Biomolecules · doi:10.3390/biom12111722 · Cited by 34
The involvement of microglia in Alzheimer's disease: a new dog in the fight
Moore, Z., Taylor, J. M., & Crack, P. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14546 · Cited by 29
Zhuang, X., Jie, L., Song, Y., Ban, R., Zhao, X., Xia, Z., Wang, Z., & Zhang, G. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08815-z · Cited by 35
“…impairing microglial phagocytic activity, ligand binding, and the ability to transition to the disease-associated microglia (DAM) state, resulting in elevated plaque burden and altered inflammatory responses (Jay et al., 2015; Kleinberger et al., 2014; Maza-heri et al., 2017; Wang et al., 2015b).”
Liu, X., Baxley, S., Hebron, M. L., Turner, R. S., & Moussa, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115044 · Cited by 41
“TREM2 promotes microglial survival, migration, and phagocytosis of apoptotic cells, making it a critical regulator of neuroinflammatory processes in the brain [43].”
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
Fujita, Y., Kano, K., Kishino, S., Nagao, T., Shen, X., Sato, C., Hatakeyama, H., Ota, Y., Niibori, S., Nomura, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88870-9 · Cited by 37
Vautheny, A., Duwat, C., Aurégan, G., Joséphine, C., Hérard, A.-S., Jan, C., Mitja, J., Gipchtein, P., Gaillard, M.-C., Buée, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105398 · Cited by 28
Desimone, A. M. L., Hong, J., Brockie, S. T., Yu, W., Laliberté, A. M., & Fehlings, M. G. (2021) · JCI Insight · doi:10.1172/jci.insight.149227 · Cited by 31
“149227 and their ability to change molecular signature and functioning during injury and disease (25, 47, 48).”
BackgroundAnimal models of Alzheimer’s disease: preclinical insights and challenges
Xu, Q., Yang, W., Zhong, M., Lin, Z., Gray, N. E., & Xian, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0001 · Cited by 44
The Microglial Response to Neurodegenerative Disease
Song, W. M., & Colonna, M. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.04.002 · Cited by 30
Fan, Y., Ma, Y., Huang, W., Cheng, X., Gao, N., Li, G., & Tian, S. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.02.002 · Cited by 30
The removal of percutaneous Kirschner wires used in the stabilisation of fractures in children.
Symons, S., Persad, R., & Paterson, M. (2005) · PubMed · Cited by 31
Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?
García‐Culebras, A., Cuartero, M. I., Peña‐Martínez, C., Moraga, A., Vázquez‐Reyes, S., Castro-Millán, F. J., Cortés‐Canteli, M., Lizasoaín, I., & Moro, M. Á. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16159 · Cited by 36
“…showed that the plaque-associated myeloid cells were likely derived from infiltrating peripheral “ inflammatory ” monocytes, based on cellular markers (Jay et al., 2015) although another study using genetic mouse models labelling different myeloid populations found that plaque-associated myeloid…”
BackgroundSiddiqui, T., Bhattarai, P., Popova, S. D., Coşacak, M. İ., Sariya, S., Zhang, Y., Mayeux, R. P., Tosto, G., & Kızıl, Ç. (2021) · Cells · doi:10.3390/cells10102748 · Cited by 30
Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs
Medrano-Jiménez, E., Meza‐Sosa, K. F., Aragon, J. A. U., Secundino, I., Pedraza-Alva, G., & Pérez-Martínez, L. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr1021-531r · Cited by 28
How the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells
Schaible, P., Henschel, J., & Erny, D. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03371-0 · Cited by 35
“Specifically, TREM2 upregulation has been found both in patients with AD and additionally in transgenic mouse models [71] [78] ( Box 1 ).”
Chen, K., Li, F., Zhang, S., Chen, Y., Ikezu, T. C., Li, Z., Martens, Y. A., Qiao, W., Meneses, A. D., Zhu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03420-8 · Cited by 35
Metadata
- Authors
- Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T.
- Affiliations
- Cleveland Clinic (US)
- The Lerner Research Institute 1 and 2
- Jackson Laboratory (US)
- Case Western Reserve University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lamb, Bruce T.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-03-02
- Volume
- 212
- Issue
- 3
- Pages
- 287-295
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4354365
- OpenAlex
- W2155344647
- Cited by
- 682
- References
- 33
- Citations by year
- 2026: 27 · 2025: 56 · 2024: 46 · 2023: 56 · 2022: 74 · 2021: 62 · 2020: 70 · 2019: 59 · 2018: 65 · 2017: 67 · 2016: 54 · 2015: 45
- FWCI
- 41.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000439)
- National Institute on Aging (R01AG023012, AG023012, F31AG048704)
- National Institute of General Medical Sciences (T32GM007250)
- National Institute of Neurological Disorders and Stroke (NS047804, T32NS067431, NS087298, R01NS088137, T32NS077888)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- TREM2, Alzheimer's disease, inflammatory macrophages, microglia, amyloid deposits, tau pathology, neuroinflammation, amyloidosis
- MeSH terms
- Age Factors, Aged, Alzheimer Disease, Animals, Disease Models, Animal, Female, Hippocampus, Humans, Macrophages, Male, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Up-Regulation, Amyloid beta-Peptides, tau Proteins, Leukocyte Common Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.